This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Organovo Celebrates Economist Technology Quarterly Coverage

SAN DIEGO, March 12, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated a profile of the company and the 3D bioprinting space as the cover story in the Economist's Technology Quarterly.

Keith Murphy, chairman and chief executive officer of Organovo, commented that "Organovo is proud to continue to receive insightful coverage in top business and financial news outlets. We appreciate the recognition as a top tier biotechnology company showing leadership in an emerging and important space."

In its coverage, the Economist's Technology Quarterly describes:
  • the role of Organovo Scientific Founder Prof. Gabor Forgacs in foundational work in the bioprinting field;
  • the potential of Organovo's bioprinted 3D Liver tissues to improve pharmaceutical toxicity testing;
  • Organovo's technology advantage in being able to make 100% cellular tissues; and
  • Organovo's work in early animal studies to create simple tissues for direct surgical implantation to treat patients; and other details of the company's strategy, technology, and operations.

In putting together their detailed coverage, the Economist's Technology Quarterly had a scientific writer visit the company, receive access to the company's facilities, and review and interview many others in the space.  Organovo worked directly with this writer over the course of two months to provide information for the piece.

Organovo has continued to receive coverage in important news outlets, such as Fox Business News and Bloomberg News in February 2014, and important customer-facing outlets such as Genetic Engineering and Biotechnology News, and Medical Device and Diagnostic Industry in January 2014.  We are further pleased to announce that our CEO, Keith Murphy, was recognized  as one of 50 fascinating people in technology by Networkworld, which recognizes innovative and inspirational work in technology. 

Organovo is also pleased to be named a 2014 Award Finalist by the internationally renowned Edison Awards™. The distinguished awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy.  The Edison Awards Steering Committee and more than 3,000 professionals from the fields of product development, design, engineering, science, marketing and education have voted the NovoTissue® Human Liver Model, as a 2014 Edison Award Finalist.  We look forward to the announcement of the winners on April 30.

As regards certain other information outlets, Organovo continues to caution investors regarding the content of certain reports targeting existing and potential investors in its common stock, especially on certain internet sites.  Organovo, like many other innovative technology companies, has been the subject of various articles on certain investor websites or from independent researchers that contain significant factual errors. The content of these reports can be submitted by independent authors, without any specific qualifications, experience or expertise required. In fact, most sites do little or no fact checking, provide little to no editorial oversight, and provide limited or no mechanisms for correction of factual errors.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.73 -0.55%
FB $119.19 1.20%
GOOG $709.82 1.20%
TSLA $215.05 1.70%
YHOO $37.29 0.95%


Chart of I:DJI
DOW 17,738.27 +77.56 0.44%
S&P 500 2,056.21 +5.58 0.27%
NASDAQ 4,729.1080 +12.0140 0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs